Cilnidipine is a calcium channel blocker. Cilnidipine is approved for use in Japan, China, India, Korea, and some European countries to treat hypertension. It is a calcium antagonist accompanied with L-type and N-type calcium channel blocking functions. Unlike other calcium antagonists, cilnidipine can act on the N-type calcium channel in addition to acting on the L-type calcium channel. It was patented in 1984 and approved for medical use in 1995. In India, the No 1 brand is CILACAR Marketed and manufactured by JB CHEMICALS AND PHARMACEUTICALS. It is also available with a combination of Telmisartan by the name of CILACAR-T manufactured by the same company.
Medical uses
Cilnidipine decreases blood pressure and is used to treat hypertension and its comorbidities. Due to its blocking action at the N-type and L-type calcium channel, cilnidipine dilates both arterioles and venules, reducing the pressure in the capillary bed. Cilnidipine is vasoselective and has a weak direct dromotropic effect, a strong vasodepressor effect, and an arrhythmia-inhibiting effect. Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients - the results of a large-scale prospective post-marketing surveillance study of post-stroke hypertensive patients treated with cilnidipine indicate that cilnidipine was effective in treating uncontrolled blood pressure and was well tolerated in post-stroke hypertensive patients. The Ambulatory Blood Pressure Control and Home Blood Pressure Lowering By N-Channel Blocker Cilnidipine trial is a large-scale clinical study on blood pressure and pulse rate in the real world with use of cilnidipine - this study revealed that Cilnidipine significantly reduced BP and PR in hypertensive patients at the clinic and at home, especially with higher BP and PR in the morning.
Side effects
The side effects could be severe dizziness, fast heartbeat, and swelling of face, lips, tongue, eyelids, hands and feet. Lesser side effects include stomach pain, diarrhea and hypotension. Peripheral edema, a common side effect from the use of amlodipine, was reduced when patients were shifted to cilnidipine.
